BRNS earnings analysis
What we found in BRNS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Barinthus Biotherapeutics reported a significant narrowing of losses in Q4 2025, with a net loss of $5.5 million compared to a loss of $19.6 million in the same period last year. Although revenue remained at $0.0, the company achieved an EPS of -0.27 which was better than the estimate of -0.37 and marks an improvement from the previous year's quarterly EPS of -0.51.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved EPS Performance
- Reported EPS improved to -0.27, beating consensus estimates of -0.37.
- Narrowed Net Loss
- Net loss was $5.5 million, down from $19.6 million the prior year.
- Cash Position Remains Solid
- Cash balances decreased to $67.2 million from $71.9 million but remained adequate for current operations.
- Free Cash Flow Improvement
- Free cash flow showed improvement to -$4 million, compared to -$18 million in the previous quarter.
- Strategic Merger Agreement
- Management is moving forward with a merger that will enhance product offerings in key therapeutic areas.
- Focus on Clinical Trials
- Continued investment in clinical trials expected to support future growth despite ongoing net operating losses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sustained Operating Losses
- The company reported cumulative losses of $309.6 million as of March 31, 2026.
- Dependence on Future Funding
- Need for additional funding indicated, especially with ongoing clinical trials and R&D.
- Regulatory Approval Risks
- Uncertainty remains regarding the timing and success of future regulatory approvals for its drug candidates.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
What they said about what is next.
Anticipated cash runway to fund operations through at least 2027.
The filing reads better than the one before it.
What came before.
- 10-K · March 13, 2026
- Barinthus repositioned in 2025 as a clinical-stage immunology company centered on its SNAP-TI antigen-specific immune tolerance platform, prioritizing VTP-1000 (celiac disease) and deprioritizing legacy viral-vector…
- 10-Q · August 7, 2025
- Barinthus reported no product revenue and posted a Q2 2025 net loss per share of $(0.52), wider than $(0.43) in Q2 2024. Operating expenses increased to $23,337 (Q2 2025) from $18,863 (Q2 2024) driven by a $8.183…
- 10-K · March 20, 2025
- Barinthus Biotherapeutics' 2024 Form 10-K emphasizes a strategic refocus on immune-tolerance (SNAP-TI) and prioritization of VTP-300 (chronic HBV) and VTP-1000 (celiac) following encouraging interim clinical data. The…
- 10-Q · November 6, 2024
- Q3 2024 results show first quarter revenue recognition of $14.969 million (license revenue) and an improvement in GAAP loss metrics: loss from operations narrowed to $(9.380) million and diluted loss per share improved…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BRNS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever